GlaxoSmithKline and Purdue look to Apple's ResearchKit for R&D

ResearchKit, the technology Apple ($AAPL) promises will transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, could become a viable tool in drug development, and two major drugmakers are working to integrated into clinical trials. As Buzzfeed reports, GlaxoSmithKline ($GSK) and Purdue Pharma are in the early stages of figuring out how to engage with ResearchKit. The platform is designed to allow medical institutions running clinical trials to design apps that keep tabs on patient-reported outcomes, measure vital signs or otherwise use the iPhone's many sensors to harvest information. The apps currently available measure symptoms of asthma, Parkinson's disease, diabetes, breast cancer and cardiovascular disease. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.